What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cancer
The scientist’s investigation covers issues in Internal medicine, Surgery, Transplantation, Oncology and Immunology.
His Internal medicine study frequently draws connections to adjacent fields such as Gastroenterology.
His Surgery research integrates issues from Risk factor and Lymphoma.
As a part of the same scientific family, David C. Linch mostly works in the field of Transplantation, focusing on Fludarabine and, on occasion, Donor lymphocyte infusion.
His Oncology study combines topics in areas such as Odds ratio, Cyclophosphamide, Non-Hodgkin's lymphoma, Case-control study and Autologous stem-cell transplantation.
He interconnects Myelopoiesis, Survival analysis and Stem cell in the investigation of issues within Immunology.
His most cited work include:
- The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. (1266 citations)
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B (1262 citations)
- Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients (912 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Immunology, Surgery, Oncology and Transplantation.
David C. Linch combines topics linked to Gastroenterology with his work on Internal medicine.
The study incorporates disciplines such as CD34 and Cancer research in addition to Immunology.
His work is dedicated to discovering how Surgery, Rituximab are connected with Diffuse large B-cell lymphoma and other disciplines.
The various areas that David C. Linch examines in his Oncology study include Myeloid leukemia, NPM1 and Minimal residual disease.
His Transplantation research includes elements of Stem cell and Fludarabine.
He most often published in these fields:
- Internal medicine (44.23%)
- Immunology (26.05%)
- Surgery (22.55%)
What were the highlights of his more recent work (between 2012-2021)?
- Internal medicine (44.23%)
- Oncology (20.80%)
- Cancer research (12.94%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Oncology, Cancer research, Rituximab and Diffuse large B-cell lymphoma.
His Internal medicine research includes themes of Gastroenterology, Surgery and Immunology.
His research integrates issues of Haematopoiesis and Incidence in his study of Immunology.
The Oncology study combines topics in areas such as Myeloid leukemia, NPM1, Univariate analysis, Genotype and Concomitant.
David C. Linch combines subjects such as T cell, Mutant, Fludarabine, CD19 and Chronic lymphocytic leukemia with his study of Cancer research.
His Rituximab study integrates concerns from other disciplines, such as Extranodal Disease, Follicular lymphoma and Chemotherapy regimen.
Between 2012 and 2021, his most popular works were:
- Assessment of Minimal Residual Disease in Standard-Risk AML. (398 citations)
- Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles (320 citations)
- Acute myeloid leukaemia. (262 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Internal medicine
- Cancer
Internal medicine, Leukemia, Myeloid, Cancer research and Immunology are his primary areas of study.
His biological study spans a wide range of topics, including Oncology and Genotype.
His studies in Leukemia integrate themes in fields like Wnt signaling pathway, DNA methylation, Molecular biology, Myeloid leukemia and Regulation of gene expression.
His study in Cancer research is interdisciplinary in nature, drawing from both Protein kinase B, Phosphoinositide 3-kinase, Cell growth, Mutation and Minimal residual disease.
He works mostly in the field of Immunology, limiting it down to topics relating to Cumulative incidence and, in certain cases, Performance status, Survival analysis and Concomitant, as a part of the same area of interest.
His Rituximab research is multidisciplinary, incorporating elements of B-cell lymphoma and Surgery.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
